mavatrep

Please contact us at for specific academic pricing.

Background

Mavatrep is a potent and orally bioavailable antagonist of TRPV1 with IC50 value of 4.6 nM [1][2]. Transient receptor potential vanilloid-1 (TRPV1) is a thermosensitive and nonselective cation channel, and is a member of the TRP channel superfamily. The channel is activated by acidic pH (<6.8), thermal stimuli (>43℃), and endogenous lipidic mediators (anandamide and oxidative metabolites of linoleic acid) [1]. Mavatrep is a potent and orally bioavailable TRPV1 antagonist. In HEK293 cells that stably express human or rat TRPV1 (rTRPV1) channels, mavatrep (1 μM) inhibited capsaicin-induced Ca2+ influx with IC50 values of 4.6 nM and 21 nM. In whole-cell patch clamp electrophysiology assay, mavatrep concentration-dependently inhibited the activation of hTRPV1 channels by pH (5.0) and capsaicin (1 μM) with IC50 values of 6.8 and 23 nM, respectively. Mavatrep (0.1 μM) also inhibited 74 ± 8.1% heat-evoked currents mediated by hTRPV1 [1]. In the CFA model of inflammatory of pain, mavatrep (10 mg/kg po) significantly reversed CFA-induced thermal hypersensitivity with ED50 and ED80 values of 1.8 and 7.8 mg/kg, respectively [1].

[1]. Parsons WH, Calvo RR, Cheung W, et al. Benzo[d]imidazole Transient Receptor Potential Vanilloid 1 Antagonists for the Treatment of Pain: Discovery of trans-2-(2-{2-[2-(4-Trifluoromethyl-phenyl)-vinyl]-1H-benzimidazol-5-yl}-phenyl)-propan-2-ol (Mavatrep). J Med Chem, 2015, 58(9): 3859-3874.